Company Overview and News
Superlon Holdings Bhd (Sept 19, RM1.29) Maintain neutral with a lower target price (TP) of RM1.23: Superlon Holdings Bhd’s results for the first quarter of financial year 2019 (1QFY19) missed forecast as net profit of RM2.85 million made up only 15% of our full-year forecast. Revenue of RM25.72 million was largely within expectations making up 22% of our full year estimates. The variance was attributed to lower-than-expected selling prices, resulting in lower gross profits.
KUALA LUMPUR (Sept 19): Superlon Holdings Bhd rose 5.83% this morning after the group said it expects its top-line growth for the financial year ending April 30, 2019 (FY19) to rise at a faster rate of 10%, mainly driven by growing production capacity at its new factory in Vietnam, and increasing sales volume.
KLANG: Thermal insulation material maker Superlon Holdings Bhd expects its top-line growth for the financial year ending April 30, 2019 (FY19) to rise at a faster rate of 10%, mainly driven by growing production capacity at its new factory in Vietnam, and increasing sales volume.
KUALA LUMPUR (Sept 19): The FBM KLCI is expected to trade range bound today and rise higher on some bargain hunting activities in line with the overnight gains at most global markets.
4863 7235 5196 MYTEF 5202 0162 3484
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484
KLANG (Sept 18): Superlon Holdings Bhd expects revenue to increase at a faster rate of 10% year-on-year (y-o-y) in the financial year ending April 30, 2019 (FY19), mainly on capacity growth driven by its new Vietnam factory and higher sales volume.
THERE is a fine line between buying the dip and catching a falling knife. In the case of thermal insulator manufacturer Superlon Holdings Bhd, which saw its share price almost halve over the past nine months, investors would have got hurt catching this falling knife.
Superlon Holdings Bhd (June 22, RM1.24) We downgrade to neutral with a revised target price (TP) of RM1.58 from RM1.82: Superlon Holdings Bhd’s earnings of RM12.3 million for the financial year ended April 30, 2018 (FY18), making up 80% of our full-year forecast.
KUALA LUMPUR (June 22): Superlon Holdings Bhd shares retreated as much as 31 sen or 20% to RM1.21 after the company reported that net profit fell to RM12.27 million for financial year ended April 30, 2018 (FY18) from RM23.72 million a year earlier.
7235 BSMAF 1818
KUALA LUMPUR (June 22): The FBM KLCI pared much of its loss at the midday break today as index-linked banking stocks advanced for the benchmark index to regain some lost ground.
HLFBF PBLOF UPBMF 4065 1082 7235 BATS 4162 1295 7153 2089 9334 KLKBY 2445 4863 5347 3026 TNABY 5819 MYTEF TNABF
KUALA LUMPUR (June 22): The FBM KLCI fell 0.66% at mid-morning today, tracking losses at the regional markets as investor sentiment remained jittery given the spectre of a global trade war.
APEXF 7090 UPBMF 4065 7235 BATS 4162 2089 9334 KLKBY 2445 4863 5347 1996 0026 TNABY MYTEF 2836 TNABF MGFCF
KUALA LUMPUR (June 11): RHB Retail Research said Superlon Holdings Bhd’s buying momentum may have returned after it recently climbed above the 21-day SMA line.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...